Brokerages Set Senseonics Holdings, Inc. (NYSE:SENS) Price Target at $1.55

Key Points

• Senseonics Holdings, Inc. has received a consensus rating of "Buy" from five brokerages, with an average target price of $1.55 over the next year.
• Significant institutional interest was noted, with Bank of America increasing its stake by 1,282.4%, now holding 915,488 shares valued at approximately $436,000.
• The stock is currently trading at $0.46, with a market cap of $373.78 million and a 1-year high of $1.40.

Senseonics Holdings, Inc. (NYSE:SENS - Get Free Report) has been assigned an average rating of "Buy" from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $1.5375.

A number of research analysts recently commented on the company. Wall Street Zen upgraded Senseonics to a "sell" rating in a report on Monday, May 12th. Barclays assumed coverage on Senseonics in a research report on Wednesday. They issued an "overweight" rating and a $1.50 target price on the stock. HC Wainwright reissued a "buy" rating and issued a $1.40 target price (up previously from $1.10) on shares of Senseonics in a research report on Tuesday, July 8th. TD Cowen assumed coverage on Senseonics in a research report on Tuesday, July 15th. They issued a "buy" rating and a $1.25 target price on the stock. Finally, Lake Street Capital raised Senseonics to a "strong-buy" rating in a research report on Thursday, July 17th.

Institutional Trading of Senseonics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. purchased a new stake in Senseonics in the fourth quarter valued at approximately $26,000. IFP Advisors Inc increased its position in shares of Senseonics by 120.9% during the first quarter. IFP Advisors Inc now owns 47,500 shares of the company's stock worth $31,000 after acquiring an additional 26,000 shares during the period. CTC Alternative Strategies Ltd. purchased a new stake in shares of Senseonics during the first quarter worth $31,000. Two Sigma Investments LP purchased a new stake in shares of Senseonics during the fourth quarter worth $36,000. Finally, Smith Salley Wealth Management purchased a new stake in shares of Senseonics during the first quarter worth $36,000. Hedge funds and other institutional investors own 12.36% of the company's stock.

Senseonics Trading Down 0.1%

SENS traded down $0.00 during trading hours on Wednesday, reaching $0.46. The company's stock had a trading volume of 3,108,361 shares, compared to its average volume of 8,040,664. Senseonics has a fifty-two week low of $0.25 and a fifty-two week high of $1.40. The stock has a market cap of $374.35 million, a PE ratio of -3.53 and a beta of 0.88. The business's 50-day moving average is $0.50 and its 200-day moving average is $0.61. The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.